SpaceandPeople Analyst Q&A: Recovery is in hand (LON:SAL)

SpaceandPeople plc (LON:SAL) is the topic of conversation when Zeus Capital’s Research Analyst Robin Byde caught up with DirectorsTalk for an exclusive interview.

Q1: I wanted you to talk to today about SpaceandPeople. What do they do and can you provide us a little bit of background to the company?


A1
: The company is a smaller business but operating in an interesting vertical and a very topical one at the moment. The company secures, sells, and manages pop-up shops and kiosks and arranges promotional events in shopping centres, public squares, and train stations. This is for a wide range of customers, including retailers and promoters and also property companies who own shopping centres.

Q2: In terms of trading, have they performed just lately? I’m guessing the COVID had some kind of affect?

A2: So, they recently reported their interims, the numbers were challenging frankly, revenue was down 72% to £1.1 million and the company reported a loss before taxation of £1.6 million but this was mainly as the business completely shut down for three months during the March national lockdown.

So, the key issues with these results, I guess, the first one is going concern, to put it bluntly is the company going bust, this looks unlikely as the company secured £1 million through the UK CBILS loan scheme, and actually the cash is in a better position than management has originally expected. So, the 30th of September, it was quite recently, the cash position was £1.6 million, now that’s compared £0.9 million for the same period the year before. The company has also achieved some good overhead cost savings so the cash position right now looks as if it’s at the low point.

Just a bit more on those costs savings so they stripped out £1.2 million in administrative costs so they reduced head count, they reorganised and streamlined and they’ve moved to new, frankly cheaper, offices in Glasgow and also they moved to new offices in Hamburg because they have a business in Germany too.

So, when the recovery starts to really kick in, operating margins could actually be structurally higher.

Q3: Now with recovery in mind, what opportunities are there for investors looking or potential investors looking at the company now?

A3: I think that’s a good point so current trading, we’re not back to normal but there are clear signs of recovery and management is saying that they are writing new business with good margins.

So, I think in terms of the recovery, there are three issues here. There’s the UK retail business, there’s the German retail busines so both of those divisions operate primarily in shopping malls and then there’s a UK rail station or train station business.

The UK railway station business primarily for Network Rail is, frankly, weak as you can imagine, with low passenger footfall through main stations such as London’s King’s cross and London Waterloo. It appears that business is going to remain in the doldrums for some time.

If you look at the German retail business, there’s actually been a pretty healthy recovery and footfall across Germany, indeed most recent German retail data indicates that footfall is above pre COVID levels, and SpaceandPeople are seeing healthy activity and healthy demand for their pop-up shops and kiosks.

UK retail is a little bit slower but is, nonetheless, recovering to.

I think, very obviously, with the ongoing COVID-19 restrictions across Europe, we have to be a bit cautious about the shape of the recovery but there is a recovery in hand.

Click to view all articles for the EPIC: ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    DirectorsTalk

    More articles like this

    Guild Esports sign two-year gaming chair sponsorship with Razer

    Guild Esports plc (LON:GILD; OTCQB: GULDF), a global teams organisation and lifestyle brand, has welcome Razer as the Company’s Official Gaming Chair Partner with the signing of a two-year global sponsorship deal. The total contract value, which

    Redde Northgate trading ahead of expectations

    Redde Northgate plc (LON:REDD), the leading integrated mobility solutions platform providing services across the vehicle lifecycle, has announced a trading update for the year ended 30 April 2022, ahead of its results for the year scheduled

    Inchcape

    Inchcape update on Russian operations

    Inchcape plc (LON:INCH) is deeply saddened by the ongoing conflict in Ukraine and the enormous humanitarian impact on all those affected. We share the hopes of the world for a peaceful resolution. In light of the current

    STRIX GROUP PLC ORD 1P

    Strix Group to conduct investor presentation on 31st March 2022

    Strix Group plc (LON:KETL), the global leader in the design, manufacture and supply of kettle safety controls and other complementary water temperature management components will be conducting an investor presentation covering their Full Year results to the period

    City of London Investment Group plc

    City of London Investment Group Barry Olliff increases holding

    City of London Investment Group plc (LON:CLIG), a leading specialist asset management group offering a range of institutional and retail products investing primarily in closed-end funds, stated that it has been notified that Stable View III LP,

    CentralNic

    CentralNic Group continue to beat expectations (Analyst Interview)

    CentralNic Group Plc (LON:CNIC) is the topic of conversation when Bob Liao Director and Research Analyst at Zeus Capital joins DirectorsTalk Interviews. Bob provides us with an overview of VGL, explains how the acquisition fits in with CentalNic’s business,

    Guild Esports wins fifth major trophy

    Guild Esports plc (LON:GILD; OTCQB: GULDF), a global team organisation and lifestyle brand, has announced that it has won its fifth major trophy after its Fortnite pro-player, Henrik Mclean (‘Hen’), achieved first place in the prestigious Fortnite

    Oncimmune signs new commercial follow-on contract 

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous